Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
2026-09-28 17:05
•David Jagielski, Cpa •The Motley Fool
••• • Axe Cap view
Why Regeneron’s Strength Doesn’t Move the Rand
Regeneron shows solid growth but South African investors should watch USD/ZAR more closely than REGN stock.
Regeneron's strong revenue growth and pipeline are impressive, particularly with Dupixent and Eylea HD driving sales. But for South African investors, the direct impact is limited. The shares trade on the US market and move in USD, so any gain is filtered through the rand’s fluctuations. Right now, USD/ZAR remains a bigger driver of local returns than Regeneron’s earnings beats. On a valuation basis, Regeneron looks cheaper than many US tech names, which tempers downside risk. Still, currency risk is real—if the rand weakens sharply, gains in Regeneron shares might be blunted. The upcoming Q3 earnings could spark some volatility, especially if guidance disappoints or the FDA delays key approvals. Given the rand’s current pressures and global volatility, local investors might want to watch USD/ZAR first, then decide on REGN after earnings. this is just our opinion and not financial advice
Hold off buying Regeneron shares directly until after Q3 earnings. Instead, focus on USD/ZAR moves; a weaker rand could justify hedging some USD exposure. Buy selectively in South African exporters instead.
- USD/ZAR
- Regeneron Pharmaceuticals (REGN)
- Rand weakness eroding US-listed gains
- Regeneron’s Q3 earnings missing expectations
5/10
Regeneron Pharmaceuticals stock has underperformed this year, down around 1%, but the company demonstrated strong fundamentals in its last earnings report with 17% revenue growth and impressive drug sales. With a modest valuation (19x trailing earnings vs. S&P 500's 23x), a robust pipeline of 50 product candidates, and upcoming Q3 earnings on Oct. 30, analysts suggest the stock could be poised for a rally and represents a solid value buy for long-term investors.
Our take is based on reporting first published by The Motley Fool.